Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial

BACKGROUND: The rVSVΔG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 × 10(7) plaque-forming units (PFU) in a trial in Guinea. This study provides further safety and immunogenicity data. METHODS AND FINDINGS: A randomised, open-label phase I trial in Lambaréné, Gabon, studied 5 single...

Descripción completa

Detalles Bibliográficos
Autores principales: Agnandji, Selidji T., Fernandes, José F., Bache, Emmanuel B., Obiang Mba, Régis M., Brosnahan, Jessica S., Kabwende, Lumeka, Pitzinger, Paul, Staarink, Pieter, Massinga-Loembe, Marguerite, Krähling, Verena, Biedenkopf, Nadine, Fehling, Sarah Katharina, Strecker, Thomas, Clark, David J., Staines, Henry M., Hooper, Jay W., Silvera, Peter, Moorthy, Vasee, Kieny, Marie-Paule, Adegnika, Akim A., Grobusch, Martin P., Becker, Stephan, Ramharter, Michael, Mordmüller, Benjamin, Lell, Bertrand, Krishna, Sanjeev, Kremsner, Peter G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630143/
https://www.ncbi.nlm.nih.gov/pubmed/28985239
http://dx.doi.org/10.1371/journal.pmed.1002402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630143/
https://www.ncbi.nlm.nih.gov/pubmed/28985239
http://dx.doi.org/10.1371/journal.pmed.1002402

Ejemplares similares